GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

Phase 2

Completed

Conditions: Anaemia

Interventions: Drug: Daprodustat
Drug: rhEPO
Drug: Ferrous sulfate containing the stable iron isotope (57Fe)
Drug: Ferrous sulfate containing the stable iron isotope (58Fe)

First Posted Date: 2018-03-07

Last Posted Date: 2024-03-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 15

Registration Number: NCT03457701

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Danirixin
Drug: Omeprazole

First Posted Date: 2018-03-07

Last Posted Date: 2021-05-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 40

Registration Number: NCT03457727

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)

Phase 2

Terminated

Conditions: Anaemia

Interventions: Drug: Daprodustat
Drug: Darbepoetin alfa
Drug: Acetylcholine
Drug: Sodium nitroprusside
Drug: L-N-monomethyl arginine acetate (L-NMMA)

First Posted Date: 2018-02-27

Last Posted Date: 2024-03-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 6

Registration Number: NCT03446612

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: GSK1795091
Drug: GSK3359609
Drug: GSK3174998
Drug: Pembrolizumab

First Posted Date: 2018-02-27

Last Posted Date: 2023-05-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 54

Registration Number: NCT03447314

Locations: 🇪🇸
GSK Investigational Site, Barcelona, Spain

A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine

Phase 2

Completed

Conditions: Respiratory Disorders

Interventions: Biological: NTHi Mcat investigational vaccine (GSK3277511A)
Biological: Placebo

First Posted Date: 2018-02-23

Last Posted Date: 2021-08-31

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 200

Registration Number: NCT03443427

Locations: 🇬🇧
GSK Investigational Site, Chippenham, United Kingdom

Extended Access of Momelotinib in Adults With Myelofibrosis

Phase 2

Active, not recruiting

Conditions: Neoplasms
Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Primary Myelofibrosis (PMF)
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Interventions: Drug: MMB

First Posted Date: 2018-02-22

Last Posted Date: 2024-05-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 237

Registration Number: NCT03441113

Locations: 🇺🇸
IC Irvine Health, Orange, California, United States
🇬🇧
GSK Investigational Site, Oxford., United Kingdom
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States

and more 111 locations